Abstract
The antifungal antibiotic, echinocandin B (ECB), was modified by a sequential procedure in which the initial step involved enzymatic removal of the native N-linoleoyl group from the N-terminus using an Actinoplanes utahensis culture. The resulting product, ECB nucleus, was reacylated using active esters or acid halides of various substituted acids to give a series of ECB analogs. These analogs possessed anti-Candida activity both in vitro and in vivo (mice). Other studies have shown that one of these, cilofungin, the 4-n-octyloxybenzoyl-ECB analog (LY121019), has excellent anti-Candida activity, low toxicity and is superior to other available antifungal antibiotics. © 1989, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION. All rights reserved.
Cite
CITATION STYLE
Debono, M., Abbott, B. J., Fukuda, D. S., Barnhart, M., Willard, K. E., Molloy, R. M., … Hunt, A. H. (1989). Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptide: Synthesis of the antifungal agent cilofungin (LY121019). The Journal of Antibiotics, 42(3), 389–397. https://doi.org/10.7164/antibiotics.42.389
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.